We initiate coverage of NeoDynamics, a medtech company transitioning from research and development into commercialisation, with their unique breast biopsy instrument NeoNavia. Tissue biopsies play a significant role in breast cancer diagnosis, and NeoDynamics' unique instrument has been specifically developed to overcome the downfalls of today's gold standard. We see several potential key catalysts in the coming six to twelve months that are positive for the stock.